检索词checkmate 032 gastric cancer; CTLA4 and Tumor Mutational Burden and gastric cancer; PD1 and Tumor Mutational Burden and gastric cancer; immune-checkpoint inhibition and Tumor Mutational Burden and gastric cancer.
CheckMate-032研究：Nivolumab和Nivolumab加上Ipilimumab在转移性食管胃癌患者中的疗效和安全性 (nih.gov)
A balancing act: dual immune-checkpoint inhibition for oesophagogastric cancer | Nature Reviews Clinical Oncology
结论：高TMB不能保证受益于免疫检查点抑制（ICI）
Current status of immune checkpoint inhibitors for gastric cancer | SpringerLink
In addition, high tumor mutational burden (TMB) [73], T-cell inflamed gene profiling and interferon-γ gene signature [74], and circulating tumor DNA (ctDNA) [75] have been also reported as possible biomarkers predicting clinical outcomes of immunotherapy by ICI
Tumor Mutational Burden and Response Rate to PD-1 Inhibition (nih.gov)
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432 - PubMed (nih.gov)
Ib / II期临床试验：高TMB可能是接受曲妥单抗单药的AGC患者OS的预测指标。
肿瘤突变负担作为胃癌PD-1抗体治疗的新生物标志物 (nih.gov)
肿瘤突变负担（TMB）最近已被描述为PD-1抗体治疗的一种新的生物标志物。但是，其在AGC中的预测作用尚未得到证实。在最近发表于《肿瘤学年鉴》上的一项研究中，Wang等人。[ 9 ]已将TMB鉴定为用托利帕单抗治疗的难治性胃癌OS获益的生物标志物。作者通过使用全外显子组测序（WES）测试了TMB，发现TMB而非PD-L1与AGC的显着生存获益相关。TMB-High组的OS明显优于TMB-Low组（14.6 vs 4.0个月，HR = 0.48，P = 0.038）。这项研究是第一个将TMB识别为ICI在胃肠道（GI）癌症中使用的预测性生物标志物。
Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer - PubMed (nih.gov)
110例使用抗PD-1 / PD-L1抗体，51例使用抗CTLA-4和PD-1 / PD-L1抗体: TMB与存活率提高相关，但是当排除MSI高的患者时未观察到这种关联。
